TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06021262

Intervention type: OTHER
Intervention: exposure to organophosphates
Description: organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.

Intervention type: OTHER
Intervention: exposure to organophosphates
Description: organophosphates are esters of phosphoric acids or Thio phosphoric acids that exist in pesticides, where patients can be chronically or acutely exposed to such compounds.
Study: NCT04901754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Plus Apatinib
Description: -Drug: camrelizumab Camrelizumab intravenous infusion was administered at a dose of 200 mg on Day 1 of each 21-day cycle,until PD.~Other Name: SHR-1210~-Drug: Apatinib Mesylate Apatinib capsules 250 mg given orally , once daily in 21-day cycle ,until PD.
Study: NCT05296681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBT-NM108
Description: Patients receive irinotecan-based chemotherapy per standard of care.
Study: NCT05166577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanatinostat
Description: Nanatinostat at the confirmed RP2D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir starting at 900 mg orally daily
Study: NCT06576804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric cycling training
Description: Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric cycling training
Description: Performed exercise training 5 days a week for 6 weeks on an eccentric ergometer.~Each training session: 5 min at 30% of maximal workload (Wmax) for warmed up and cold down and 30 min the main training phase.~Intensity: Firstly, set at 60% Wmax, and progressively increased 5% per week
Study: NCT05127811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: BION design
Study: NCT05252325

Intervention type: DEVICE
Group type: OTHER
Intervention: hyaluronic acid plus lidocaine
Description: local injection for correction of nasolabials fold

Intervention type: DEVICE
Group type: OTHER
Intervention: hyaluronic acid plus lidocaine
Description: local injection for correction of nasolabials fold

Intervention type: DEVICE
Group type: OTHER
Intervention: hyaluronic acid without lidocaine
Description: local injection for correction of nasolabial folds

Intervention type: DEVICE
Group type: OTHER
Intervention: hyaluronic acid without lidocaine
Description: local injection for correction of nasolabial folds
Study: NCT05166577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir starting at 900 mg orally daily
Study: NCT05127811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: BION design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: BION design
Study: NCT06509633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience education and standard rehabilitation regime
Description: Median nerve gliding exercises, wrist and forearm muscle stretches, wrist mobilizations and finger joint mobilizations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard Rehabilitation regime
Description: standard Rehabilitation regime
Study: NCT06331351

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: 2 times a day, 1 sachet each time.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea liquid packets
Description: 2 times a day, 1 sachet each time.
Study: NCT05651321

Intervention type: OTHER
Intervention: Samples materials of basic taste stimuli and enteral nutrition preparations
Description: Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.

Intervention type: OTHER
Intervention: Samples materials of basic taste stimuli and enteral nutrition preparations
Description: Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
Study: NCT05166577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (anti-PD-1) dosed at 200 mg intravenous (IV) every 3 weeks
Study: NCT05496088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-PVI only
Description: Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-PVI only
Description: Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Re-PVI + substrate ablation
Description: Comparison of two treatment strategies of persistent AF catheter ablation:~Re-PVI vs. Re-PVI + continuous complex activity mapping and ablation.
Study: NCT06382467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate + propofol MCT
Description: remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol MCT
Description: Propofol MCT 2-8 mcg/ml using target-controlled infusion
Study: NCT05778149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib,Anlotinib
Description: Aumolertinib 110mg p.o QD; Anlotinib 12mg, oral for 2 weeks, three weeks a cycle, until disease progression.
Study: NCT05063019

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging and enterography before surgery
Study: NCT05651321

Intervention type: OTHER
Intervention: Samples materials of basic taste stimuli and enteral nutrition preparations
Description: Samples materials of basic taste stimuli were used, i.e. reference substances tartaric/citric acid (acidic), quinine hydrochloride/caffeine (bitter), anhydrous sodium chloride (salty), sucrose (sweet), and quercetin/alum (astringent) and six different flavored enteral nutrition preparations.
Study: NCT04737629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancy and Water
Description: In the expectancy and water condition, participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script for this condition will inform them of research that has shown water to decrease appetite by up to 50% (attempting to create an expectancy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Expectancy and Water
Description: Participants will be instructed to consume the mint herb and 500mL of water before the start of the taste test. The script will inform them of research that has shown water to decrease appetite by up to 50%. In this condition, however, the research team will also inform them that this herb is expected to counteract the effects of water on appetite because it decreases water retention, causing water to pass through the stomach and intestines at a faster than normal rate (attempting to create no water expectancy or nullify any pre-existing expectancy).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Water
Description: Participants will be instructed to consume the mint herb and 50mL of water before the start of the taste test. Participants will be given 100mL of water during the taste test to aid in their ability to taste and consume food, and to avoid acute thirst interfering with food consumption. Access to fluids during a taste test has been used in control conditions in similar studies. The script for this condition will inform participants of research that has shown water to decrease appetite by up to 50% but acknowledge that they will not be receiving water (thus, they should not expect an effect on appetite).
Study: NCT06154798

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: World Digital Detox Women's Health Program
Description: World Digital Detox Women's Health Program incorporates gradual steps, including mindfulness exercises, setting boundaries on digital usage, decluttering digital spaces, promoting offline connections, and encouraging mindful technology use.
Study: NCT05522998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: Ciprofol (0.4-0.5mg/kg) for anesthesia induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol(2-2.5mg/kg) for anesthesia induction
Study: NCT06096142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solaris DE
Description: Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solaris DE
Description: Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
Study: NCT06217133

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Conventional CPAP will be administered according to the unit's routine on ventilators of different brands and models according to service availability. Binary prongs, from brands available in the service, will be used as an interface without touching the nasal septum with the size recommended by the manufacturer and in accordance with the protocol established in the unit.~TThe CPAP bubbles will be administered using the CPAP NEONATAL BABYPAP® MODEL 1150 S equipment, which is an electromedical device for non-invasive ventilatory assistance for newborns that generates continuous pressure in the airways (CPAP) controlled by means of a column of water that bubbles, through a flow of heated and humidified medical gas mixture supplied by a breathing circuit to the patient's nasal passage.
Study: NCT06096142

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PTA
Description: Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
Study: NCT06198153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stationary Cycling
Description: In addition to the conventional physical therapy, children in this group will receive 10-15 minutes of stationary cycle training, 3 times a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Functional Training
Description: In addition to the conventional physical therapy, the training will follow a 6-week progressive functional training program for lower extremities. These exercises will include sit-to-stand exercise, lateral/forward step-up exercise (i.e. climbing a stair or stepping up onto a kerb), and half-knee rise exercise (i.e. rising from the ground). All exercises will be performed in 1-3 sets of 10-15 repetitions, with a 90 second rest in between the sets. Each exercise will be performed within 10-15 minutes. Training session will be given 3 times a week. During the training, intensity will be progressively increased by increasing the repetitions
Study: NCT06377813

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mode-Kinetic Chain Exercise With Core Stability Exercises
Description: the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mode-Kinetic Chain Exercise
Description: the interventions will be given for 35-45 mins. All the participants will follow the same standardized exercise protocol 5 days a week, for 12 weeks.
Study: NCT06182111

Intervention type: PROCEDURE
Intervention: Intraoperative morphine
Description: Morphine dose = 0,1 mg mg/kg (maximum 10 mg) intravenous given 20 min after start of surgery
Study: NCT04676477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion at a starting dose of 3.2 mg/kg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at 40 mg or 80 mg once daily
Study: NCT04775680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG106 injection
Description: ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle
Study: NCT05534269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous muscle precursor cells
Description: Patients own Muscle Precursor Cells are isolated and injected into the rhabdomyosphincter
Study: NCT04775680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG106 injection
Description: ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADG106 injection
Description: ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody injection
Description: PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody injection
Description: PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 antibody injection
Description: PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle
Study: NCT05073458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisinib
Description: parsaclisib will be administered QD orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally follwed by Parsaclisinib in the open label period
Study: NCT05427669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
Study: NCT04676477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at RCD 1 (and at RCD 2 if two provisional RCDs are selected in dose escalation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion 5.6 mg/kg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion 5.6 mg/kg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER3-DXd
Description: Intravenous infusion 4.8 mg/kg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at 80 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Oral administration at 80 mg once daily
Study: NCT06031740

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sclerotherapy with 1.5% polidocanol
Description: 2mL (3%) polidocanol = 60mg; maximal dose: 1mL/column and 4mL/session.~- Group 2: Foam sclerotherapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foam sclerotherapy.
Description: Tessari's technique; 4mL 3% poilidocanol +16mL air; maximal dose: 2mL/column and 20mL/session.
Study: NCT05917535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalizing course
Description: 6 hour mental health education course about mentalizing.
Study: NCT04947865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Electrical stimulation of peripheral nerves to measure resulting gait kinematics and surface muscle activity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial knee brace
Description: Knee brace used to limit knee mobility in healthy individuals to imitate stroke survivors and measure resulting gait kinematics and surface muscle activity.
Study: NCT05084027

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: venetoclax combining with fludarabine and melphalan
Description: Venetoclax 400mg/day，oral，day-8～day-2; Fludarabine, 30mg/m2/day，intravenous，d-7～d-3；Melphalan, 140mg/ m2/d，intravenous，day-2
Study: NCT05689320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: EMA-based intervention
Description: This study will compare the effect of fixed and incremental incentive strategies on compliance rates. All participants will be promised a basic incentive. An additional gift voucher will be given to intervention group participants who comply with the intervention at least 85% of the time, whereas a basic incentive will only be given to control group participants.
Study: NCT05427669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 12 cycles at the most
Study: NCT04938895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Black Respondents Exposure to a Photo
Description: Black survey respondents will be randomly assigned to one of four treatments. In each treatment arm, the subject will view a photo of an NIH investigator. We experimentally vary treatment along two dimensions: whether the investigator is a man v. woman and whether the man is white vs. black. We will survey participants' willingness to participate in a clinical trial and how their initial response is impacted by other characteristics such as perceived trustworthiness and quality.
Study: NCT04852744

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Description: Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Description: Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups.

Intervention type: OTHER
Group type: OTHER
Intervention: Brain MRI
Description: Anatomical MRI The anatomical data will be acquired by means of a 3T Signa Premier General Electric Healthcare MRI, allowing the acquisition of classic anatomical sequences (T1, T2) and a high-resolution hippocampal sequence allowing to accurately apprehend its various sub-fields. (total acquisition time: 10 min).~The hippocampal volume, the orbital-frontal cortex and the cingulate cortex will be measured by voxel-based morphometry (VBM; Ashburner \& Friston, 2000\]) using the SPM software (Statistical Parametric Mapping; Friston et al., 2006). The voxel-by-voxel morphometric analysis of T1 MRI images makes it possible to classify and segment the different brain tissues (gray matter versus white matter) and to analyze the focal differences in volume within these tissues between the different groups.
Study: NCT05077852

Intervention type: DIAGNOSTIC_TEST
Intervention: Urethrocystoscopy
Description: Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urethrocystoscopy
Description: Patients diagnosed with a primary bladder cancer at the base, trigone or neck of the bladder with USG in the urology clinic will be evaluated with urethrocystoscopy. With urethrocystoscopy, patients definitive diagnosed with bladder cancer and IPP.
Study: NCT06251128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Self management Program
Description: Our educational and behavioral program includes an educational component, problem-solving to overcome barriers to a healthy lifestyle, activities of daily living, and management of medications.~No drugs or devices will be delivered to the participants
Study: NCT06528678

Intervention type: DEVICE
Intervention: Intraocular lens
Description: Lens exchange with an intraocular lens
Study: NCT04868409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suxamethonium
Description: 1 mg/kg for tracheal intubation after 60 seconds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: 1 mg/kg for tracheal intubation after 60 seconds
Study: NCT05555082

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: 10 times of 30 minutes Swedish classical Massage will be given monthly during one year. The massage will be give by a cerified masseur